Regulatory Environment - The FDA regulatory environment under new leadership is the most significant macro factor influencing XBI's performance over the next 12 months, with clarity on agency leadership being crucial for biotech valuations [1] - The operational capacity of the FDA will determine whether XBI's one-year momentum can be sustained, as consistent regulatory approval timelines are necessary to avoid valuation compression across all holdings [4][14] Fund Performance - The SPDR S&P Biotech ETF (XBI) has over $8 billion in assets and is primarily focused on healthcare, with 96% of its portfolio in this sector [2] - Year-to-date, XBI is up approximately 2%, but has seen a 4% pullback in the last 30 days; however, it has increased by 46% over the past year [2] - Despite the recent gains, the fund is still down about 6% over the past five years, reflecting the impact of the 2021-2022 rate-driven selloff [2] Fund Structure and Strategy - XBI employs an equal-weight structure, giving each biotech company roughly the same portfolio weight, which creates unique opportunities and risks for investors [3] - This equal-weight approach means that a single clinical event can significantly impact the entire fund, unlike cap-weighted indices [9] Key Holdings and Developments - Moderna (MRNA) is the largest position in XBI at 2.3% weight, with expectations for phase 3 data on norovirus and melanoma in 2026, and has rallied 82% year to date [5][10] - Krystal Biotech (KRYS) reported $204 million in net income for 2025, with a 34% year-over-year revenue growth for VYJUVEK, and has phase 3 readouts expected before year-end [5][11] - Sarepta Therapeutics (SRPT) is recovering from a 33% revenue decline in Q4 2025 and anticipates returning to profitability in 2026 [5][12] - Recursion Pharmaceuticals (RXRX) is down 23% year to date due to dilution concerns from a $300 million equity offering [5][13] Market Concerns - Recent FDA staffing cuts and broader restructuring within HHS have raised concerns about the review capacity and continuity of advisory committees, which could slow the regulatory approval pipeline [7] - A slower approval pipeline could compress valuations across XBI's holdings, particularly affecting small and mid-cap companies that lack commercial revenue [7]

Core Viewpoint - The performance of the SPDR S&P Biotech ETF (XBI) in 2026 will be significantly influenced by the Phase 3 data from Moderna (MRNA), Sarepta Therapeutics (SRPT), and Krystal Biotech (KRYS) as well as the regulatory environment under the FDA's new leadership [2][8]. Group 1: ETF Performance and Structure - The SPDR S&P Biotech ETF (XBI) has over 150 equal-weight positions and has increased by 46% over the past year, but it faces near-term challenges due to FDA staffing cuts that may slow the regulatory approval process [2][7]. - The fund has over $8 billion in assets, with 96% of its portfolio in healthcare, and is up about 2% year to date, although it has seen a 4% pullback in the last month [7]. - The equal-weight structure of XBI means that each clinical readout impacts the entire fund significantly, unlike cap-weighted indices [11]. Group 2: Company-Specific Insights - Moderna (MRNA), the largest position in XBI at 2.3% weight, anticipates Phase 3 data for norovirus and melanoma in 2026 and has rallied 82% year to date, partly due to a patent settlement [12]. - Krystal Biotech (KRYS) reported $204 million in net income for 2025, with VYJUVEK revenue growing 34% year over year, and has Phase 3 readouts expected before year-end [13]. - Sarepta Therapeutics (SRPT) is recovering from a 33% decline in ELEVIDYS revenue in Q4 2025 and aims to return to profitability in 2026, contingent on label rehabilitation and a recent launch in Japan [14]. Group 3: Regulatory Environment - The FDA's operational capacity under new leadership is a critical factor for XBI's performance, as consistent regulatory approval timelines are necessary to avoid valuation compression across its holdings [3][8]. - Concerns about FDA staffing reductions and restructuring have raised questions about review capacity, which could lead to a slower approval pipeline affecting small and mid-cap companies the hardest [9]. - Monitoring the FDA's published PDUFA action dates and advisory committee calendars is essential, as delays or unexpected refusals would signal potential issues [10].

Core Insights - The company has guided to a net product revenue of $1.2 billion to $1.4 billion for 2026, with a comfortable consensus estimate of $900 million for PMO revenue [1] - The projected revenue for ELEVIDYS in 2026 is expected to be between $300 million and $500 million, with a floor run rate of $500 million if no other changes occur [1] Group 1 - The company reported $110 million in the current quarter, which annualizes to approximately $440 million, highlighting the dynamics of a one-time therapy compared to a chronically dosed therapy [2][3]

Summary of Sarepta Therapeutics FY Conference Call Company Overview - **Company**: Sarepta Therapeutics (NasdaqGS:SRPT) - **Event**: FY Conference Call on March 03, 2026 Key Points Financial Guidance - Sarepta guided to 2026 net product revenue of **$1.2 billion to $1.4 billion**, with a comfortable consensus estimate of **$900 million** for PMO revenue, implying **$300 million to $500 million** for ELEVIDYS revenue [1][2][3] Product Dynamics - The company emphasized the difference between one-time therapies and chronically dosed therapies, noting that the revenue from a one-time therapy starts from zero each quarter [2][4] - The turnaround time for patient treatment is approximately **six months**, which affects revenue recognition [2][13] Sales Force Expansion - Sarepta is expanding its sales force, doubling the number of representatives, with a focus on peripheral sites and patient finding [2][30][46] - The first wave of sales representatives has been hired and trained, with a contract sales force also being utilized [2][41][45] Q1 Revenue Expectations - The company anticipates a **15% decline** in Q1 revenue due to factors such as prescription requirements for each child and potential patient cancellations due to illnesses [2][53][59] Efficacy and Safety Data - The sales force is focusing on detailing the efficacy data, particularly the three-year EMBARK data, while addressing safety concerns in context [2][67][70] - Physicians have responded positively to the EMBARK data, finding it consistent with their experiences [2][71][73] Clinical Trials and Data - Enrollment for non-ambulant patients in the Cohort 8 study has begun, with five sites currently open for dosing [2][90][92] - The primary endpoint for the study will focus on the rate of Acute Liver Injury (ALI) [2][96] Competitive Landscape - Sarepta is preparing for competition from a direct competitor, EXONDYS, by emphasizing the long-term efficacy and safety profile of its PMOs [2][246][260] - The company does not anticipate significant flexibility in pricing due to the small patient population [2][247] Future Developments - Sarepta is working on a combination approach using the TRiM platform with PMOs, with updates expected in **2027** [2][288][296] - The company is also developing a proprietary DUX4-related gene knockdown biomarker, with ongoing validation work [2][222][228] Regulatory Engagement - Sarepta plans to meet with the FDA to discuss potential full approval for its products, with a focus on the data supporting their market presence [2][263][271] Conclusion - Sarepta Therapeutics is navigating a complex landscape with its gene therapy products, focusing on expanding its sales force, managing revenue expectations, and preparing for competitive pressures while emphasizing the efficacy and safety of its therapies [1][2][3][4]

Core Insights - Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is considered a promising investment opportunity in the biotech sector despite recent price target reductions by analysts [1][2]. Group 1: Analyst Ratings and Price Targets - Wells Fargo reduced its price target for Sarepta from $45 to $38 while maintaining an Overweight rating, citing a longer-than-expected timeline for the GTx launch post-safety events [1]. - Baird also lowered its price target from $22 to $20, maintaining a Neutral rating, after updating its model based on the company's fiscal Q4 and full-year financial results [2]. Group 2: Financial Performance - For the full year 2025, Sarepta reported net product revenues of $1.864 billion, which includes $965.6 million from PMO and $898.7 million from ELEVIDYS [2]. - In fiscal Q4 2025, net product revenues reached $369.6 million, comprising $259.2 million from PMO and $110.4 million from ELEVIDYS [2]. Group 3: Company Overview - Sarepta is a commercial-stage biopharmaceutical company focused on RNA-targeted therapeutics and gene therapy for rare diseases, with approved products for Duchenne muscular dystrophy and ongoing development for other disorders [3].

Financial Data and Key Metrics Changes - For the full year 2025, total revenues were $2.2 billion, an increase of 16% year-over-year, including $1.86 billion in net product revenue and $334 million in collaboration, contract manufacturing, and royalty revenue [35][36] - The company exited 2025 with $954 million in cash and investments, growing $89 million in the fourth quarter [6][40] - The company anticipates being cash flow positive and profitable on a non-GAAP basis in 2026, despite ongoing investments in its pipeline and marketed therapies [6][7] Business Line Data and Key Metrics Changes - Net product revenue for 2025 totaled $1.86 billion, with $966 million from the PMO franchise and $899 million from ELEVIDYS [17] - For the fourth quarter, net product revenues for the PMOs totaled $259 million, stable compared to Q4 2024, with individual PMO revenues of $148 million for EXONDYS 51, $34 million for VYONDYS 53, and $77 million for AMONDYS 45 [17][18] - Fourth quarter revenues for ELEVIDYS totaled $110 million, impacted by a severe flu season and rescheduled infusions [17] Market Data and Key Metrics Changes - The company expects total net product revenue for 2026 to be in the range of $1.2 billion to $1.4 billion for approved therapies, with a flat to down 15% revenue expectation for Q1 2026 compared to the previous quarter [14][15] - The company has launched ELEVIDYS in Japan and expects to record a $40 million milestone payment from Roche upon the first commercial sale in Q1 2026 [36] Company Strategy and Development Direction - The company is focused on transitioning AMONDYS and VYONDYS to traditional approval based on the positive results from the ESSENCE study and plans to engage with the FDA [7][8] - The company is addressing information deficits regarding ELEVIDYS to ensure patients and physicians have a comprehensive understanding of its benefits and risks [10][21] - The company is committed to executing commercial initiatives to accelerate demand for ELEVIDYS and enhance educational outreach to clinicians and patients [23][24] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in 2025 but expresses confidence in the company's strong financial position and the potential of its therapies [6][42] - The management emphasizes the importance of timely treatment with ELEVIDYS to prevent irreversible muscle damage in Duchenne patients [20][75] - Management is optimistic about the company's pipeline, particularly the siRNA programs, and is preparing for potential pivotal studies [32][70] Other Important Information - The company has a robust siRNA pipeline with five clinical stage programs and additional preclinical work for CNS diseases [16][32] - Management announced the intention of the CEO to retire by the end of 2026, citing family commitments and a personal connection to muscular dystrophy [43][44] Q&A Session Summary Question: How does the board view internal versus external candidates for CEO succession? - The board is considering both internal and external candidates, emphasizing the importance of continuity and understanding the company's culture and challenges [48][50] Question: What metrics will indicate initial receptivity to ELEVIDYS? - Key metrics include enrollment forms and infusions, along with feedback from advisory boards and market research [55][56] Question: What benchmarks should be considered for siRNA readouts? - Important benchmarks include safety and muscle concentration, with expectations for continued dose escalation based on preclinical data [61][64] Question: When will pivotal studies for siRNA programs begin? - The company is preparing for phase three studies and is moving as quickly as possible, depending on data from ongoing studies [70][71] Question: How are clinicians currently risk stratifying patients for ELEVIDYS? - Clinicians consider various factors such as liver enzymes, age, weight, and steroid exposure, but the company believes there is still a significant opportunity for patient dosing [74][75]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues were $2.2 billion, an increase of 16% year-over-year, including $1.86 billion in net product revenue and $334 million in collaboration, contract manufacturing, and royalty revenue [35][36] - The company exited 2025 with $954 million in cash and investments, growing $89 million in the fourth quarter [6][40] - The company anticipates being cash flow positive and profitable on a non-GAAP basis in 2026, despite ongoing investments in its pipeline and marketed therapies [6][14] Business Line Data and Key Metrics Changes - Net product revenue for 2025 totaled $1.86 billion, with $966 million from the PMO franchise and $899 million from ELEVIDYS [17] - For the fourth quarter, net product revenues for PMOs totaled $259 million, stable compared to Q4 2024, with individual PMO revenues of $148 million for EXONDYS 51, $34 million for VYONDYS 53, and $77 million for AMONDYS 45 [17][18] - Fourth quarter revenues for ELEVIDYS totaled $110 million, impacted by a severe flu season and rescheduled infusions [17] Market Data and Key Metrics Changes - The company expects a revenue range of $1.2 billion to $1.4 billion for 2026 from approved therapies, with a flat to down 15% revenue expectation for Q1 2026 compared to the previous quarter [14][36] - The company noted that the safety events of 2025 reshaped perceptions of gene therapy and ELEVIDYS, indicating a critical reset year for the ambulatory patient population [18][24] Company Strategy and Development Direction - The company aims to transition AMONDYS and VYONDYS to traditional approval based on accumulated real-world evidence and scheduled discussions with the FDA [7][8] - The company is focused on addressing information deficits regarding ELEVIDYS to ensure patients and physicians have a comprehensive understanding of its benefits and risks [10][22] - The company is advancing its siRNA pipeline with five clinical stage programs and plans to announce preliminary data for DM1 and FSHD programs by the end of Q1 2026 [16][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for ELEVIDYS and the transformational nature of the therapy, despite acknowledging challenges in the near term [15][24] - The management highlighted the importance of preserving muscle through early treatment with ELEVIDYS, supported by muscle MRI data showing the consequences of delayed treatment [20][76] - Management indicated that the company is on a strong financial footing with four approved therapies and a robust pipeline, despite the challenges faced in 2025 [43][44] Other Important Information - Doug Ingram, the CEO, announced plans to retire by the end of 2026, citing family commitments and a personal connection to muscular dystrophy due to family diagnoses [44][46] - The company is conducting a comprehensive search for Ingram's successor, focusing on candidates who can continue the company's mission and drive execution [46] Q&A Session Summary Question: Thoughts on internal vs external candidates for CEO succession - The board is considering both internal and external candidates, emphasizing the importance of continuity and understanding the company's challenges [49][50] Question: Key metrics for initial receptivity to ELEVIDYS messaging - The ultimate signals will be enrollment forms and infusions, with additional insights from regional advisory boards and market research [56][57] Question: Benchmarks for siRNA readouts in Q1 - Key metrics to watch include safety and muscle concentration, with expectations for continued dose escalation based on preclinical data [62][63] Question: Timeline for pivotal studies for siRNA programs - The company is preparing for phase III studies and is moving as fast as possible towards potential accelerated approval [69][71] Question: Current risk stratification for ELEVIDYS candidates - The company believes there is a significant opportunity for ELEVIDYS, with a focus on educating physicians and patients about the therapy's benefits [75][76]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues were $2.2 billion, an increase of 16% year-over-year, including $1.86 billion in net product revenue and $334 million in collaboration, contract manufacturing, and royalty revenue [33] - The company exited 2025 with $954 million in cash and investments, growing $89 million in the fourth quarter [4] - The company reported a GAAP operating loss of $700 million and a non-GAAP operating loss of $492 million for 2025 [38] Business Line Data and Key Metrics Changes - Net product revenues for the PMOs totaled $259 million in Q4 2025, stable compared to Q4 2024, with individual PMO revenues of $148 million for EXONDYS 51, $34 million for VYONDYS 53, and $77 million for AMONDYS 45 [15] - Fourth quarter revenues for ELEVIDYS totaled $110 million, impacted by a severe flu season and rescheduled infusions [15] Market Data and Key Metrics Changes - The company anticipates total net product revenue for 2026 to be in the range of $1.2 billion to $1.4 billion for approved therapies, with a guidance of $1.2 billion without educational efforts [12][34] - The company expects to record a $40 million milestone payment from Roche upon the first commercial sale of ELEVIDYS in Japan in Q1 2026 [34] Company Strategy and Development Direction - The company aims to transition AMONDYS and VYONDYS to traditional approval based on the results of the ESSENCE study and has scheduled a meeting with the FDA [5] - The company is focused on addressing information deficits regarding ELEVIDYS to ensure patients and physicians have a comprehensive understanding of its benefits and risks [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity and profitability on a non-GAAP basis in 2026 while fully investing in the pipeline and marketed therapies [4] - Management acknowledged that 2026 serves as a critical reset year for the ambulatory patient population regarding ELEVIDYS, emphasizing the need for clear communication of its risk-benefit profile [16] Other Important Information - The CEO announced plans to retire by the end of 2026, citing family commitments and a personal connection to muscular dystrophy due to family diagnoses [42][44] - The company has an exciting siRNA pipeline with five clinical stage programs and plans to announce preliminary data from proof-of-concept studies for DM1 and FSHD at the end of Q1 2026 [14][31] Q&A Session Summary Question: How does the board view internal versus external candidates for CEO succession? - The board is considering both internal and external candidates, emphasizing the importance of continuity and understanding the company's culture and challenges [48] Question: What metrics will indicate initial receptivity to ELEVIDYS? - Key metrics include enrollment forms and infusions, along with feedback from regional advisory boards and market research [55] Question: What are the benchmarks for siRNA readouts in Q1? - The focus will be on safety and muscle concentration, with expectations for continued dose escalation based on preclinical data [62] Question: When will pivotal studies for siRNA begin? - The company is preparing for phase three studies and is moving as fast as possible towards potential accelerated approval [70] Question: How are clinicians currently risk stratifying patients for ELEVIDYS? - Clinicians are considering various factors such as liver enzymes and age, but the company believes there is a significant opportunity to educate on the benefits of early dosing [74]

Patients can't wait for the next breakthrough in medical research. So neither will we. Fourth Quarter and Full-Year 2025 Financial Results Wednesday, February 25, 2026 In order to provide Sarepta's investors with an understanding of its current results and future prospects, forward-looking statements will be made during this presentation. Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," ...

FDA Approvals & Rejections - Intellia Therapeutics has received FDA approval to resume its MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran (nex-z) targeting hereditary transthyretin amyloidosis with polyneuropathy, increasing target enrollment from 50 to 60 patients [2][4] - Outset Medical's next-generation Tablo Hemodialysis System has been granted FDA 510(k) clearance, making it the first dialysis device to meet enhanced cybersecurity standards, with shipping expected to begin in Q2 2026 [6][7] - OKYO Pharma has received positive feedback from the FDA for its Phase 2b/3 trial design for Urcosimod, a candidate for neuropathic corneal pain, with plans to start the trial in the first half of 2026 [8][9] - REGENXBIO has faced clinical holds on its RGX-111 and RGX-121 gene therapy programs due to a case of CNS tumor in a child treated with RGX-111, although no similar findings were reported in other patients [10][11] - Almirall has received NMPA approval for Seysara in China for treating moderate-to-severe acne vulgaris, expanding its dermatology portfolio in the region [12][13] Clinical Trials - Breakthroughs - Aprea Therapeutics reported early clinical activity for APR-1051 in endometrial cancer, achieving a 50% reduction in target lesion size in a patient with PPP2R1A-mutated uterine serous carcinoma [19][21] - Fractyl Health's Revita demonstrated positive results in weight maintenance after GLP-1 drug discontinuation, showing a 4.5% weight regain compared to 7.5% in the sham group [22][24] - Ascletis Pharma announced positive Phase 3 results for Denifanstat in moderate-to-severe acne vulgaris, focusing on long-term safety in a trial with 240 patients [25][26] - GRI Bio reported new gene expression data from its Phase 2a study of GRI-0621 in idiopathic pulmonary fibrosis, showing significant improvements in lung injury and fibrosis progression [27][28] - Cardiff Oncology announced encouraging results from its Phase 2 trial of Onvansertib in RAS-mutated metastatic colorectal cancer, with a well-tolerated regimen and plans to advance to a registrational program [31][32] - Genentech's CT-388 Phase 2 trial for obesity showed a significant placebo-adjusted weight loss of 22.5% at 48 weeks, with a high percentage of participants achieving significant weight loss [34][36] - Sarepta Therapeutics reported positive three-year results from its EMBARK study for ELEVIDYS in Duchenne muscular dystrophy, showing significant slowing of disease progression in treated patients [38][41] Deals - YD Bio Limited has signed a letter of intent to acquire Safe Save Medical for approximately $26.87 million, aiming to enhance its capabilities in advanced cellular therapeutics [14][15][17]